Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Muscle Recovery and Fatigue01:24

Muscle Recovery and Fatigue

Muscle fatigue refers to the decline in a muscle's ability to maintain the force of contraction after prolonged activity. It primarily stems from changes within muscle fibers. Even before experiencing muscle fatigue, one may feel tired and have the urge to stop the activity. This response, known as central fatigue, occurs due to changes in the central nervous system, namely the brain and spinal cord. While there is no single mechanism that induces fatigue, it may serve as a protective response...
Fatigue01:21

Fatigue

Fatigue occurs when materials rupture under repeated or fluctuating loads, even at stress levels far below their static breaking strength. It typically results in brittle failure, even for ductile materials. It is a critical consideration in designing machines and structural components subjected to repetitive or varying loads. The nature of these loadings can range from fluctuating loads like unbalanced pump impellers causing vibrations to repeatedly bending a thin steel rod wire back and forth...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the ฮฑ1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impacts of human and digital scribes on improving physician wellness and reducing administrative burden: a scoping review protocol.

BMJ openยท2026
Same author

Patients before paperwork: a feasibility study evaluating digital and human scribes in psychiatric clinical settings - a randomised controlled trial protocol.

BMJ openยท2026
Same author

Gifts, Blind Spots, and Gray: Canadian Student Pharmacists' Perceptions of Pharmaceutical Industry Interactions.

American journal of pharmaceutical educationยท2026
Same author

Drug Coverage Policy and Legacy Prescribing: A Cross-Sectional Analysis in British Columbia.

Health science reportsยท2026
Same author

Sustainability pharmacy assistants in large urban hospital system.

The International journal of pharmacy practiceยท2026
Same author

Rising Escitalopram Use in British Columbia: Is it Rational and Evidence-Informed?

Canadian journal of psychiatry. Revue canadienne de psychiatrieยท2025

Related Experiment Video

Updated: May 22, 2026

The Treadmill Fatigue Test: A Simple, High-throughput Assay of Fatigue-like Behavior for the Mouse
09:25

The Treadmill Fatigue Test: A Simple, High-throughput Assay of Fatigue-like Behavior for the Mouse

Published on: May 31, 2016

Carnitine for fatigue in multiple sclerosis.

Aaron M Tejani1, Michael Wasdell, Rae Spiwak

  • 1Therapeutics Initiative, University of British Columbia, Vancouver, Canada. Aaron.Tejani@fraserhealth.ca.

The Cochrane Database of Systematic Reviews
|May 18, 2012
PubMed
Summary
This summary is machine-generated.

Carnitine supplementation does not appear to improve quality of life or reduce fatigue in multiple sclerosis (MS) patients. More research is needed to determine carnitine

More Related Videos

Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis
08:48

Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis

Published on: January 29, 2016

Related Experiment Videos

Last Updated: May 22, 2026

The Treadmill Fatigue Test: A Simple, High-throughput Assay of Fatigue-like Behavior for the Mouse
09:25

The Treadmill Fatigue Test: A Simple, High-throughput Assay of Fatigue-like Behavior for the Mouse

Published on: May 31, 2016

Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis
08:48

Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis

Published on: January 29, 2016

Area of Science:

  • Neurology
  • Clinical Trials
  • Pharmacology

Background:

  • Fatigue affects up to 92% of multiple sclerosis (MS) patients, often being the most debilitating symptom.
  • A significant portion of MS patients consider fatigue their primary and most disabling symptom.

Purpose of the Study:

  • To evaluate the efficacy of carnitine supplementation in improving quality of life and reducing fatigue in MS patients.
  • To identify potential adverse effects associated with carnitine use for MS-related fatigue.

Main Methods:

  • Comprehensive literature search of multiple databases (Cochrane, MEDLINE, EMBASE, clinicaltrials.gov) and reference lists.
  • Inclusion of randomized controlled trials and quasi-randomized trials of carnitine interventions in adults with MS-related fatigue.
  • Standardized data extraction and quality assessment of included trials.

Main Results:

  • One ongoing and one completed randomized controlled trial were identified.
  • The completed trial compared acetyl L-carnitine with amantadine; no significant difference in adverse event withdrawal rates was observed.
  • Carnitine's effects on fatigue remain unclear, with no reported data on mortality or quality of life.

Conclusions:

  • Insufficient evidence currently supports carnitine as a therapeutic advantage over placebo or active comparators for MS-related fatigue.
  • Results from an ongoing trial are anticipated to provide further clarity on carnitine's efficacy.
  • Further research is necessary to definitively establish carnitine's role in managing MS fatigue.